Feeds:
Posts
Comments

Archive for the ‘Boehringer Ingelheim’ Category

TODAY’S NEWS

So, have we been pursuing the wrong course for GERD all this time? Is it actually caused by immune system cells, not stomach acid?

Maybe cheap/old/tried-and-true really is better. Diuretics for HPB, for instance. Or just plain generic simvastatin for cholesterol.

Pfizer gets good news on Revatio (which is the same as Viagra, by the way) for the treatment of PAH; Spiriva for COPD; and the Prevnar 13 vaccine.

Genzyme: Train wreck?. But wait – there’s more.

Getting excited about sex: not so easy to be excited about B-I‘s experimental treatment for female desire; Vivus‘ competitor to current ED drugs still on track, however.

RECOMMENDED

Marketing/Sales – tele-detailing. Is your company looking to augment its promotional voice with telesales, virtual detailing, and other “surround sound” solutions? Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Blind Spots and Broken Limbs. I’ve got them, too…

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Whew! The back-to-back conference marathon is now over, and we can get back to our regular pharma news reporting. Here’s what’s up today…

TODAY’S NEWS

Everyone’s talking about the Zetia/Niaspan study – its results, its significance, its limitations. Bottom line – I can’t see how this can be good for Merck. More here. And Jim Edwards analyzes the damage control spin effort here.

Always a headline topic: female sexual desire treatments. The more you read about this drug (experimental ‘flibanserin’ from Boehringer-Ingelheim), however, the more you wonder if the purported effect will be worth the expense and the side effects.

BMS pushing Mead-Johnson out of the nest. It is amazing to me how drug companies cycle through periods where they diversify, then spin divisions off…

Novartis: half a dose of H1N1 vaccine may be enough. Now that’s how to increase vaccine supply!

If you’re going to blow the whistle, I guess it’s important to get on to the field of play! Whistleblower lawsuit against J&J dismissed.

RECOMMENDED

Leadership – talent selection. How is your organization choosing leaders? Impactiviti’s provider network has proven, best-in-class talent selection/management solutions. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Is this drug a frog, or a prince? I dunno, but I like the picture…!

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Note: Impactiviti Daily is going to be published somewhat irregularly over the next couple of weeks, as we’re in the heart of “conference” season and I’m attending/speaking at several events over the next month. We’ll do our best to keep you updated!

TODAY’S NEWS

FDA approves Arzerra (from GSK) for last-ditch treatment of CLL (cancer)

Boehringer-Ingelheim gets additional approvals for Micardis, including a combo drug (Twynsta)

Vertex gets positive results for its experimental Hep C drug – but I bet this headline gets more traction.

Kids getting fat on Zyprexa.

RECOMMENDED

Product Launch Training. Impactiviti’s partner network includes top-notch developers of therapeutic and product training – on-line, print, and live. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for brainstorming and recommendations.

PLUS

My review of last week’s Digital Pharma conference. It was, in some ways, a ground-breaking event.

Business buzz-jargon reaches a new height. You just can’t make this stuff up!

JUST FOR FUN

This is a very cool visual illusion. The curveball.
—–——–
Coming up next week:

eComm

Nov. 3-4 – eyeforpharma’s 4th Annual eCommunication and On-line Marketing Summit, Philadelphia, PA. I’ll be part of a panel on social networking, and live-blogging/Twittering. Here’s a discount code to save $400 off your registration: SPEAK

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

B-I gets (European) clearance for extended-release Parkinson’s drug formulation.

Avodart + Flomax – a good combo for your prostate? – The drug was shown, when given with tamsulosin, to have benefits for men with prostate enlargement. In the four-year CombAT study Avodart (dutasteride) and tamsulosin together showed a 66% reduction in the risk of acute urinary retention (AUR) or benign prostatic hyperplasia (BPH)-related surgery compared to tamsulosin alone. And the GSK-sponsored study, published online in European Urology, found a 20% risk reduction in these factors compared to Avodart on its own. Part of the results’ significance lies in the fact that tamsulosin is the active ingredient in Boehringer Ingelheim‘s Flomax, one of Avodart’s rivals in this therapy areamore

Glaxo starts getting hit with judgments over Paxil/birth defect link – A Pennsylvania state court jury deliberated seven hours before finding the drug maker failed to properly warn docs and pregnant women about the risks of the antidepressant. This was the first of 600 cases, by the waymore

From NPR – Selling Sickness: How drugs ads changed healthcare – It used to work like this: Doctors decided what to prescribe. Drug companies — through medical advertisers — tried to influence doctors. Patients did what they were toldmore

RECOMMENDED

Leadership and Management Development. Impactiviti’s partner network has a broad range of offerings, from assessments to customized workshops to simulations and much, much more. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for brainstorming and recommendations.

PLUS

This is an imaginative and well-structured presentation on the U.S. healthcare system, in simple terms: Healthcare Napkins (named by BusinessWeek as one of the world’s best presentations of 2009)

JUST FOR FUN

Business buzzwords – one of the best collections you’ll ever see, in one “memo”! Deep-dive breakout.Coming up this month:

Oct. 26-27 – Kru Research’s e-Patient Connections conference, Philadelphia, PA. I’ll be speaking and live-blogging. Here’s a discount code to save $500 off your registration: SW500

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Where to get your overview of Social Media in Pharma? Right here: http://bit.ly/socialrx

TODAY’S NEWS

Pharma’s new hot properties - vaccines.

Boehringer Ingelheim pressing forward with its experimental DPP-4 inhibitor for diabetes – Boehringer Ingelheim Pharmaceuticals, Inc. today announced the conclusion of the linagliptin pivotal Phase III clinical trials, including more than 4,000 patients in 40 countries worldwide. Phase II data for linagliptin were presented earlier this year at the annual American Diabetes Association (ADA) Scientific Sessions. Full results from the Phase III trials will be presented at international scientific congresses in 2010 and beyond...more

Merck’s diabetes drug Januvia significantly lowers blood sugar – A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia®’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two yearsmore

RECOMMENDED

Product/Launch training. The Impactiviti Partner Network has great providers to help you develop your new product training – print, on-line, and live. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Has the game changed in a dramatic way in pharma social media? I think it may be likely – my initial thoughts on Google’s Sidewiki tool, which allows user commentary on ANY site.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

See the newly-re-launched Impactiviti Collection e-newsletter! Here’s a link to the on-line sample; you can sign up to receive the Connection (~every two weeks) right here.

TODAY’S NEWS

Pfizer and Wyeth to sell off some Animal Health assets to Boehringer-Ingelheim.

Speaking of B-I, here’s a presentation from them on how they successfully use Twitter. Boehringer is one of the more engaged and interactive companies in the space.

Eli Lilly‘s Alimta improves survival for lung cancer.

RECOMMENDED

District/Regional Manager development workshops. If you’re looking to developing your FLMs in a variety of skills, our best-in-class training providers can customize a program for your needs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Podcast today discussing latest social media in pharma developments, and upcoming Digital Pharma conference in October. Archived here.

JUST FOR FUN

Is it candy? Or medicine? This poster‘s both funny and a bit…scary.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

AstraZeneca’s experimental drug may bring serious competition to Plavix - AstraZeneca‘s new pill Brilinta for preventing heart attacks works better than Plavix, the world’s second biggest selling drug, without increasing the amount of life-threatening bleeding, researchers said on Sundaymore

B-I‘s new drug Praxada poised to finally provide an alternative to warfarin – Patients at risk of stroke due to an erratic heartbeat should soon have a viable alternative to 50-year-old warfarin, after a new pill from Boehringer Ingelheim beat expectations in a major clinical studymore Plus, new B-I drug for COPD is looking promising.

Encouraging results for Angiomax in cardiac mortality/survival study – The Medicines Company today announced the publication of one-year results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack and received angioplasty were significantly less likely to suffer cardiac death and had significantly better overall survival if treated with Angiomax (bivalirudin) compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI)more

FDA to Allos: not so sure about your lymphoma data – Food and Drug Administration reviewers, in a summary prepared for an advisory panel, said their two issues with Allos’ application were “the clinical significance of tumor response and duration of response” as well as “whether the benefit:risk ratio is favorable” for Folotynmore

RECOMMENDED

Technology. Learning Management Systems. On-line assessment. eMarketing. Social Media. If you’re looking for expertise, and/or for vendor connections in the technology sphere, Impactiviti can help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Couldn’t stop myself from including a link to this press release – can you discover what in the world the product being discussed is for? Neither can I…

JUST FOR FUN

Turn up your speakers, sit back for a minute or two, and just enjoy this remarkable video. Rain.

On a personal note: Next week one of my sons joins the Marines. Some thoughts from a proud Dad.

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

« Newer Posts - Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 29 other followers